Vimarsana
Biggest News Aggregation in the World

Combination Trials News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Combination Trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Combination Trials Today - Breaking & Trending Today

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progres - Vimarsana News

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progres

Combination Trials with Avutometinib (VS-6766) Ongoing as Part of Development Program Designed to Maximize Potential Across RAS Pathway-Driven TumorsCompany Confirms Q4 FDA Meeting Based on Encouraging Results to Date in Ongoing RAMP 201 Trial of Avutometinib (VS-6766) ± Defactinib in Low-Grade Serous Ovarian Cancer...

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant - Vimarsana News

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-month FDA review Positive EMERALD study data previously announced on October 20, 2021 First, and currently only, investigational oral SERD with positive topline results Additional data presented at SABCS (December 2021) and ASCO (June 2022) Plan to file marketing authorization application for elacestrant in the EU in 2H 2022 FLORENCE, Italy and BOSTON, June 23, 2022 /PRNewswire/ -- The Menarini Group ("Menarini") and Radius Health, Inc. (...

BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting - Vimarsana News

BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--May 19, 2021-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and updates from its broad portfolio will be presented at the 2021 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held June 4 – 8, 2021. “We are pleased to share updates from our growing clinical portfolio across solid tumors and hematologic malignancies at this year’s ASCO, including multiple novel combinations ...